PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
BIGT.L vs. BTEE.L
Performance
Return for Risk
Dividends
Drawdowns
Volatility

BIGT.L vs. BTEE.L

Last updated Apr 2, 2026

Compare and contrast key facts about L&G Pharma Breakthrough UCITS ETF (BIGT.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L).

BIGT.L and BTEE.L are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIGT.L is a passively managed fund by Legal & General that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Jan 18, 2018. BTEE.L is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Mar 5, 2018. Both BIGT.L and BTEE.L are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

BIGT.L vs. BTEE.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in L&G Pharma Breakthrough UCITS ETF (BIGT.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

BIGT.L vs. BTEE.L - Yearly Performance Comparison

2026 (YTD)20252024202320222021202020192018
BIGT.L
L&G Pharma Breakthrough UCITS ETF		2.31%27.03%-3.16%-14.88%2.68%-2.30%23.89%9.47%1.02%
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)		5.00%23.36%0.03%0.55%-1.41%0.37%23.80%20.78%-7.80%
Different Trading Currencies

BIGT.L is traded in GBp, while BTEE.L is traded in USD. To make them comparable, the BTEE.L values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, BIGT.L achieves a 2.31% return, which is significantly lower than BTEE.L's 5.00% return.

BIGT.L

1D
1.91%
1M
1.91%
YTD
2.31%
6M
8.11%
1Y
27.45%
3Y*
4.50%
5Y*
2.83%
10Y*
—

BTEE.L

1D
2.02%
1M
-0.24%
YTD
5.00%
6M
19.22%
1Y
35.84%
3Y*
10.48%
5Y*
5.51%
10Y*
—
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

L&G Pharma Breakthrough UCITS ETF

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)

Often compared with BIGT.L:
BIGT.L vs. INDABIGT.L vs. BCHN.LBIGT.L vs. WBIO.LBIGT.L vs. HLTW.LBIGT.L vs. WHCE.LBIGT.L vs. GLGG.LBIGT.L vs. GNOG.L
Often compared with BTEE.L:
BTEE.L vs. VOOBTEE.L vs. NBTK.DEBTEE.L vs. DOCT.LBTEE.L vs. WHCE.LBTEE.L vs. GNOG.LBTEE.L vs. WBIO.LBTEE.L vs. SBIO.L

BIGT.L vs. BTEE.L - Expense Ratio Comparison

BIGT.L has a 0.49% expense ratio, which is higher than BTEE.L's 0.35% expense ratio.

BIGT.L
L&G Pharma Breakthrough UCITS ETF
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)

Return for Risk

BIGT.L vs. BTEE.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
BIGT.L
BIGT.L Risk / Return Rank: 7474
Overall Rank
BIGT.L Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
BIGT.L Sortino Ratio Rank: 7272
Sortino Ratio Rank
BIGT.L Omega Ratio Rank: 6262
Omega Ratio Rank
BIGT.L Calmar Ratio Rank: 8787
Calmar Ratio Rank
BIGT.L Martin Ratio Rank: 7575
Martin Ratio Rank
BTEE.L
BTEE.L Risk / Return Rank: 8686
Overall Rank
BTEE.L Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
BTEE.L Sortino Ratio Rank: 8585
Sortino Ratio Rank
BTEE.L Omega Ratio Rank: 7777
Omega Ratio Rank
BTEE.L Calmar Ratio Rank: 8989
Calmar Ratio Rank
BTEE.L Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIGT.L vs. BTEE.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF (BIGT.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

BIGT.LBTEE.LDifference

Sharpe ratio

Return per unit of total volatility

1.38

1.63

-0.25

Sortino ratio

Return per unit of downside risk

1.90

2.20

-0.30

Omega ratio

Gain probability vs. loss probability

1.24

1.29

-0.04

Calmar ratio

Return relative to maximum drawdown

2.98

3.52

-0.54

Martin ratio

Return relative to average drawdown

8.68

12.98

-4.31

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BIGT.L vs. BTEE.L - Sharpe Ratio Comparison

The current BIGT.L Sharpe Ratio is 1.38, which is comparable to the BTEE.L Sharpe Ratio of 1.63. The chart below compares the historical Sharpe Ratios of BIGT.L and BTEE.L, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading graphics...

Sharpe Ratios by Period

BIGT.LBTEE.LDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.38

1.63

-0.25

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.17

0.27

-0.10

Sharpe Ratio (All Time)

Calculated using the full available price history

0.24

0.33

-0.09

Correlation

The correlation between BIGT.L and BTEE.L is 0.81, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Dividends

BIGT.L vs. BTEE.L - Dividend Comparison

BIGT.L has not paid dividends to shareholders, while BTEE.L's dividend yield for the trailing twelve months is around 0.36%.

TTM20252024202320222021202020192018
BIGT.L
L&G Pharma Breakthrough UCITS ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)		0.36%0.37%0.46%0.39%0.44%0.25%0.17%0.14%0.07%

Drawdowns

BIGT.L vs. BTEE.L - Drawdown Comparison

The maximum BIGT.L drawdown since its inception was -30.23%, roughly equal to the maximum BTEE.L drawdown of -30.88%. Use the drawdown chart below to compare losses from any high point for BIGT.L and BTEE.L.

Loading graphics...

Drawdown Indicators

BIGT.LBTEE.LDifference

Max Drawdown

Largest peak-to-trough decline

-30.23%

-38.29%

+8.06%

Max Drawdown (1Y)

Largest decline over 1 year

-11.62%

-14.02%

+2.40%

Max Drawdown (5Y)

Largest decline over 5 years

-30.23%

-38.29%

+8.06%

Current Drawdown

Current decline from peak

-1.88%

-2.70%

+0.82%

Average Drawdown

Average peak-to-trough decline

-10.72%

-13.78%

+3.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.41%

2.81%

+0.60%

Volatility

BIGT.L vs. BTEE.L - Volatility Comparison

L&G Pharma Breakthrough UCITS ETF (BIGT.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) have volatilities of 7.53% and 7.30%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

BIGT.LBTEE.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.53%

7.30%

+0.23%

Volatility (6M)

Calculated over the trailing 6-month period

14.17%

14.22%

-0.05%

Volatility (1Y)

Calculated over the trailing 1-year period

19.80%

21.94%

-2.14%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.69%

20.79%

-4.10%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.36%

22.44%

-4.08%